Cargando…

Multiple sclerosis–like lesions and type I interferon signature in a patient with RVCL

Detalles Bibliográficos
Autores principales:	Schuh, Elisabeth, Ertl-Wagner, Birgit, Lohse, Peter, Wolf, Waltraud, Mann, Johannes F., Lee-Kirsch, Min Ae, Hohlfeld, Reinhard, Kümpfel, Tania
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2014
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277301/ https://www.ncbi.nlm.nih.gov/pubmed/25566545 http://dx.doi.org/10.1212/NXI.0000000000000055

Ejemplares similares

Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations
por: Schuh, Elisabeth, et al.
Publicado: (2015)

Lesion evolution and neurodegeneration in RVCL-S: A monogenic microvasculopathy
por: Ford, Andria L., et al.
Publicado: (2020)

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
por: Spadaro, Melania, et al.
Publicado: (2016)

Multiple sclerosis and subclinical neuropathology in healthy individuals with familial risk: A scoping review of MRI studies
por: Mortazavi, Matin, et al.
Publicado: (2021)

Immune signatures of prodromal multiple sclerosis in monozygotic twins
por: Gerdes, Lisa Ann, et al.
Publicado: (2020)

Optical coherence tomography angiography biomarkers of microvascular alterations in RVCL-S
por: Al-Nofal, Mays, et al.
Publicado: (2022)

Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations (RVCL-S): An update on basic science and clinical perspectives
por: Wilms, A.E., et al.
Publicado: (2022)

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
por: Gerdes, Lisa Ann, et al.
Publicado: (2016)

DNA methylation signatures of monozygotic twins clinically discordant for multiple sclerosis
por: Souren, Nicole Y., et al.
Publicado: (2019)

PW02-032 - CNS manifestations and NLRP3/CIAS1 gene mutations
por: Kümpfel, T, et al.
Publicado: (2013)

First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine
por: Havla, Joachim, et al.
Publicado: (2021)

High clinical heterogeneity in a Chinese pedigree of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S)
por: Xie, Nina, et al.
Publicado: (2021)

Neurological manifestations in autoinflammatory syndromes: a series of 131 patients from our neuroimmunology departement
por: Schuh, E, et al.
Publicado: (2015)

Histopathology and clinical course of MOG-antibody-associated encephalomyelitis
por: Spadaro, Melania, et al.
Publicado: (2015)

Delayed diagnosis of extraovarian teratoma in relapsing anti-NMDA receptor encephalitis
por: Kümpfel, Tania, et al.
Publicado: (2016)

Plasma lipidomics of monozygotic twins discordant for multiple sclerosis
por: Penkert, Horst, et al.
Publicado: (2020)

Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood
por: Günther, Claudia, et al.
Publicado: (2023)

Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid
por: Wuhrer, Manfred, et al.
Publicado: (2015)

P02-030 - Unusual CNS manifestation
por: Schuh, E, et al.
Publicado: (2013)

Antibody signatures in patients with histopathologically defined multiple sclerosis patterns
por: Stork, Lidia, et al.
Publicado: (2020)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Aicardi-Goutières syndrome due to a paternal mosaic IFIH1 mutation
por: Tüngler, Victoria, et al.
Publicado: (2019)

Significance of Interferon-γ in Coronary Artery Bypass Surgery
por: Alrawi, Sadir J., et al.
Publicado: (2001)

Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair
por: Havla, Joachim, et al.
Publicado: (2022)

Twin study reveals non-heritable immune perturbations in multiple sclerosis
por: Ingelfinger, Florian, et al.
Publicado: (2022)

PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
por: Reuss, Reinhard
Publicado: (2013)

Biomarkers in Multiple Sclerosis
por: Martin, Roland, et al.
Publicado: (2006)

Are there cognitive and neuroimaging signatures in long COVID?
por: Matias-Guiu, Jordi A, et al.
Publicado: (2023)

4H leukodystrophy: Mild clinical phenotype and comorbidity with multiple sclerosis
por: DeGasperis, Stephanie M., et al.
Publicado: (2020)

Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation
por: Skrabl-Baumgartner, Andrea, et al.
Publicado: (2017)

Occurrence of Psoriatic Arthritis during Interferon Beta 1a Treatment for Multiple Sclerosis
por: Toussirot, Éric, et al.
Publicado: (2014)

Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta
por: Bustamante, Marta F., et al.
Publicado: (2013)

Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β
por: De Felice, Bruna, et al.
Publicado: (2014)

Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic Sclerosis
por: Vlachogiannis, Nikolaos I., et al.
Publicado: (2020)

Acceptance of the Extracare Program by Beta Interferon-Treated Patients With Multiple Sclerosis: Results of the Explore Study
por: Freidel, Matthias, et al.
Publicado: (2015)

Vestibular paroxysmia entails vestibular nerve function, microstructure and endolymphatic space changes linked to root-entry zone neurovascular compression
por: Kierig, Emilie, et al.
Publicado: (2022)

Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
por: Lehmann-Horn, Klaus, et al.
Publicado: (2011)

Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology
por: Calabresi, Peter A., et al.
Publicado: (2010)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Interferon Treatment of Multiple Sclerosis
por: Alajbegovic, Azra, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e5ope9956m455titmt1p5ikca0